Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

PBT2 recommended for orphan designation in Europe

April 28, 2015

Prana to present at New York Academy of Science Symposium on November 29th

July 17, 2013

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

May 6, 2019May 9, 2019

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Prana Biotechnology Investor Presentation

Related Posts

PBT2 recommended for orphan designation in Europe

Prana to present at New York Academy of Science Symposium on November 29th

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting